Fulcrum Therapeutics, Inc. lost $1.18 per diluted share in fiscal year 2025. This represents a decrease of 637.5% from the prior fiscal year. Over the trailing 12 months, Q3 FY2025 through Q2 FY2026, the same line adds up to a loss of $1.21 per diluted share. The table below carries 8 fiscal years, from 2018 to 2025, and the quarters Fulcrum Therapeutics, Inc. has filed alongside them.
FY2025 annual
EPS (Diluted)-$1.18
YoY-637.5%
Source SEC Filings (10-K/10-Q)Latest period Q2 FY2026, ended Jun 30, 2026ReportedCurrency USD
Annual figures, oldest first. Point at a bar to read its period.
FULC EPS (Diluted) by Fiscal Year
Figures are as reported in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.
Diluted earnings per share divides net income by the share count the company would have if every option and convertible security were exercised, which is the more conservative of the two per-share figures a filer reports.
What was Fulcrum Therapeutics, Inc.'s diluted earnings per share in fiscal year 2025?
Fulcrum Therapeutics, Inc. lost $1.18 per diluted share in fiscal year 2025.
How fast is Fulcrum Therapeutics, Inc.'s diluted earnings per share growing?
Fulcrum Therapeutics, Inc. (FULC) diluted earnings per share fell by 637.5% year over year, from -$0.16 to -$1.18 in fiscal year 2025.
What is Fulcrum Therapeutics, Inc.'s diluted earnings per share over the last twelve months?
Fulcrum Therapeutics, Inc. (FULC) reported a loss of $1.21 per diluted share over the trailing 12 months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings.
What was Fulcrum Therapeutics, Inc.'s diluted earnings per share in the most recent quarter?
Fulcrum Therapeutics, Inc. (FULC) reported -$0.34 in diluted earnings per share in Q2 2026. This represents a decrease of 21.4% from the same quarter a year earlier.
What does diluted earnings per share mean on a financial statement?
Diluted earnings per share divides net income by the share count the company would have if every option and convertible security were exercised, which is the more conservative of the two per-share figures a filer reports. This page lists what Fulcrum Therapeutics, Inc. (FULC) reported on that line in every period on record.
